On Tuesday, Mastercard Inc(NYSE:MA)’s shares declined -1.06% to $92.06.
MasterCard Incorporated (MA) declared that its Board of Directors has declared a quarterly cash dividend to holders of shares of its Class A common stock and Class B common stock. The cash dividend of 16 cents per share will be paid on November 9, 2015 to holders of record of its Class A common stock and Class B common stock as of October 9, 2015.
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services. It also offers value-added services, such as loyalty and reward programs, and information and consulting services.
Advanced Semiconductor Engineering (ADR) (NYSE:ASX)’s shares dropped -2.21% to $5.31.
Advanced Semiconductor Engineering, Inc. (ASX) declared that the Company’s public tender offer for Siliconware Precision Industries Co., Ltd shares is conducted in accordance with the applicable rules and regulations. The Company reiterates that it seeks to explore avenues of cooperation with SPIL but otherwise intends its investment in SPIL to be a pure financial investment. ASE will not intervene in SPIL’s operations and therefore could not possibly affect the rights and interests of SPIL’s employees through this Tender Offer.
Moreover, throughout our long-term operations in the industry, our Company has nurtured talents and created numerous employment opportunities for Taiwan. In the past ten years, the number of ASE employees in Taiwan raised from 25,274 to 35,686 as of this year. We have always viewed our employees as the Company’s greatest asset. As such, we strive to create a favorable work environment and conditions for our employees to fulfill our social responsibility.
Advanced Semiconductor Engineering, Inc. provides semiconductor packaging and testing services in the United States, Taiwan, Asia, Europe, and internationally. It operates through Packaging, Testing, and Electronic Manufacturing Services (EMS) segments.
At the end of Tuesday’s trade, Perrigo Company, (NYSE:PRGO)‘s shares dipped -1.64% to $171.97.
Perrigo Company plc (NYSE:PRGO) declared it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration approval for the generic version of Valeant Pharmaceutical International, Inc.’s BenzaClin® Topical Gel. The FDA concluded that Perrigo’s product is therapeutically equivalent to BenzaClin® Gel 1%/5% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as BenzaClin® Gel 1%/5% when used under the conditions specified in the label. Shipments to customers will start right away.
BenzaClin® Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending July 2015 were $231 million.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments.
Heron Therapeutics Inc (NASDAQ:HRTX), ended its Tuesday’s trading session with -3.20% loss, and closed at $33.56.
Heron Therapeutics, Inc. (HRTX), declared positive, top-line results from its Phase 2 clinical study of HTX-011 in the administration of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. The primary and all key secondary endpoints in the study were met with a high degree of statistical significance.
This randomized, placebo-controlled, double-blind, Phase 2 clinical study in 64 patients undergoing bunionectomy evaluated the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, contrast to placebo.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
